score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical	Preclinical		Copy Number	MIR17HG	Amplification				0.0	0.0		Putatively Actionable	Neoadjuvant chemotherapy + surgery	Chemotherapy + Surgical removal	Combination therapy	Amplification of the 13q31-34 region, which contains MIR17HG, was associated with increased sensitivity to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.	Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.	https://doi.org/10.2147/OTT.S105760	Investigate Actionability	Neoadjuvant chemotherapy + surgery	Chemotherapy + Surgical removal	Combination therapy	Deletion of the 13q31-34 region, which contains MIR17HG, was associated with resistance to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.	Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.	https://doi.org/10.2147/OTT.S105760						0				MIR17HG Amplification		KIRP-B3-8121	TCGA-B3-8121-01	
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 5	version 2	0.206						Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	COSMIC Signature 5 is associated with somatic ERCC2 mutations, which may suggest sensitivity to cisplatin based chemotherapy.	Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-606.	https://doi.org/10.1038/ng.3557													0				COSMIC Signature (version 2) 5 (21%)		KIRP-B3-8121		
Investigate Actionability	Clinical trial			Copy Number	BRCA2	Amplification				0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.	Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.	https://doi.org/10.1056/NEJMoa1506859													0				BRCA2 Amplification	1.0	KIRP-B3-8121	TCGA-B3-8121-01	
Investigate Actionability			Guideline	Copy Number	RB1	Amplification				0.0	0.0																Investigate Actionability	0.0	Deletion of chromosome 13 seems to have an amplifying effect on cell cycle gene expression and is reported to be associated with short event-free survival (EFS) and overall survival (OS). This copy loss event results in haploinsufficiency of RB1 and other genes mapped to chromosome 13.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	0				RB1 Amplification		KIRP-B3-8121	TCGA-B3-8121-01	
Biologically Relevant				Copy Number	FLT3	Amplification				0.0	0.0																					0				FLT3 Amplification		KIRP-B3-8121	TCGA-B3-8121-01	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.63_64insAAP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.63_64insAAP (Insertion)		KIRP-B3-8121		
Biologically Relevant				Mutational Signature	COSMIC Signature 19	version 2	0.274																									0				COSMIC Signature (version 2) 19 (27%)		KIRP-B3-8121		
